ArticleInternational journal of pharmaceutics: X2026
Focused ultrasound-mediated blood-brain barrier opening enhances delivery of Rg3 ginseng nanoparticles in a Parkinson's disease mouse model.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB) severely restricts the delivery of neuroprotective compounds to the brain, limiting therapeutic strategies for Parkinson's disease (PD). Ginsenoside Rg3, a bioactive component of ginseng, has demonstrated neuroprotective potential, but its efficacy is constrained by poor BBB permeability. Here, we evaluated focused ultrasound (FUS)-mediated BBB opening (FUS BBBO) to enhance delivery of Rg3-loaded nanoparticles in a rotenone-induced mouse model of PD. Localized FUS sonications were applied to induce transient BBB disruption, followed by intraperitoneal administration of FITC-labeled Rg3 nanoparticles. In vivo and Ex vivo fluorescence imaging confirmed a significant increase in brain accumulation of nanoparticles after FUS BBBO. While Rg3 nanoparticle treatment alone showed moderate increases in ATP levels and Complex I activity, FUS alone produced comparable trends with slightly higher recovery. The combination treatment with FUS-mediated BBBO demonstrated higher mean values (ATP: 0.27 ± 0.06; Complex I: 1.98 ± 0.41) compared to the PD group, along with improvements in motor performance. These findings suggest that FUS-BBBO may enhance the delivery of Rg3 nanoparticles to the brain and support mitochondrial function. Overall, the combination approach showed a trend toward improved outcomes; however, further studies are required to confirm these effects and establish therapeutic potential for solid statistical analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.